Journal article
Comprehensive evaluation of targeted multiplex bisulphite PCR sequencing for validation of DNA methylation biomarker panels
D Lam, PL Luu, JZ Song, W Qu, GP Risbridger, MG Lawrence, J Lu, M Trau, D Korbie, SJ Clark, R Pidsley, C Stirzaker
Clinical Epigenetics | BMC | Published : 2020
Abstract
Background: DNA methylation is a well-studied epigenetic mark that is frequently altered in diseases such as cancer, where specific changes are known to reflect the type and severity of the disease. Therefore, there is a growing interest in assessing the clinical utility of DNA methylation as a biomarker for diagnosing disease and guiding treatment. The development of an accurate loci-specific methylation assay, suitable for use on low-input clinical material, is crucial for advancing DNA methylation biomarkers into a clinical setting. A targeted multiplex bisulphite PCR sequencing approach meets these needs by allowing multiple DNA methylated regions to be interrogated simultaneously in one..
View full abstractGrants
Funding Acknowledgements
This work is supported by the National Health and Medical Research Council (NHMRC) project grant (1106870 - SJC, GPR, RP, MGL) and fellowships (1063559 and 1156408 - SJC; 1002648 and 1102752 - GPR), Cancer Australia (1044458 - GPR), National Breast Cancer Foundation IIRS Grant (IIRS-18-137 - CS), National Foundation and Medical Research and Innovation grant (NFMRI) (CS), Cancer Council NSW (RG-18-09 - RP, SJC) and the Victorian Government through the Victorian Cancer Agency (Fellowship MCRF18017 -MGL). Computational resources were provided by the Australian Government through NCI Raijin under the National Computational Merit Allocation Scheme 2019, project wk73 (SJC, PLL)